Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Google Secures Pentagon AI Deal for Classified Projects 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
LEIDEN, the Netherlands, April 20, 2017 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that Gerard Platenburg, Chief Innovation Officer, will present at the 42nd Annual Deutsche Bank Health Care Conference on Wednesday, May 3, 2017 at 12:50pm ET. The conference is being held at the InterContinental Boston Hotel in Boston, MA, USA.
The live and archived webcast of the presentation will be accessible from the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Events and Presentations’. The archived webcasts will be available for 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as cystic fibrosis, Leber’s congenital amaurosis Type 10 and dystrophic epidermolysis bullosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*
Contact:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
[email protected]
